Recent Updates
Recently added Catalysts
ANIP Positive Sentiment

ANI Pharmaceuticals to Present at September Investor Conferences

Key Takeaway: ANI Pharmaceuticals announced that its CEO and executive team will participate in upcoming investor conferences. The company aims to enhance its visibility and investor relations through these events. ANI focuses on developing innovative therapeutics across multiple therapeutic areas, including rare diseases and generics.

Market Sentiment Analysis

POSITIVE FACTORS

  • ANI Pharmaceuticals is actively engaging with investors.
  • The company is committed to sustainable growth in various therapeutic areas.
  • Leadership participation in conferences indicates strong company visibility.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+19%
120-day peak, hindsight
Typical move
1.6%
average across 3 past catalysts
Lead asset
fluocinolone acetonide
Phase 3 · Diabetic Macular Edema

Full Press Release Details

PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team, will participate in fireside chats at the following upcoming investor conferences:
Event 2026 Wells Fargo Healthcare Conference
Date Thursday, September 10, 2026
Time 1:30 p.m. ET
Webcast Click here
Event Morgan Stanley 24th Annual Global Healthcare Conference
Date Monday, September 14, 2026
Time 7:00 a.m. ET
Webcast Click here
Event H.C. Wainwright 28th Annual Global Investment Conference
Date Tuesday, September 15, 2026
Time 12.00 p.m. ET
Webcast Click here
The live and archived webcasts will also be accessible from the Company’s website at www.anipharmaceuticals.com, in the Investors section under Events and Presentations.

About ANI

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.

Investor Relations: Irina Koffler, Vice President, Investor Relations T: 917-734-7387 E: Irina.koffler@anipharmaceuticals.com

Media Relations: Argot Partners T: 212-600-1494 E: ani@argotpartners.com

SOURCE: ANI Pharmaceuticals, Inc.

Frequently Asked Questions

Who will represent ANI Pharmaceuticals at the conferences?

Nikhil Lalwani, the CEO, along with the executive leadership team, will represent ANI.

Where can I access the conference webcasts?

The live and archived webcasts will be available on ANI's website under Events and Presentations.

What is the focus of ANI Pharmaceuticals?

ANI Pharmaceuticals focuses on developing and commercializing innovative therapeutics across various therapeutic areas.

What areas does ANI's Rare Disease business cover?

The Rare Disease business markets products in ophthalmology, rheumatology, nephrology, neurology, and pulmonology.

Last updated: Sep 3, 2026